1.1.................... moves to amend S.F. No. 1425, the first engrossment, as follows:
1.2Page 1, after line 7, insert:

"1.3    Section 1. Minnesota Statutes 2015 Supplement, section 151.01, subdivision 27,
1.4is amended to read:
1.5    Subd. 27. Practice of pharmacy. "Practice of pharmacy" means:
1.6    (1) interpretation and evaluation of prescription drug orders;
1.7    (2) compounding, labeling, and dispensing drugs and devices (except labeling by
1.8a manufacturer or packager of nonprescription drugs or commercially packaged legend
1.9drugs and devices);
1.10    (3) participation in clinical interpretations and monitoring of drug therapy for
1.11assurance of safe and effective use of drugs, including the performance of laboratory tests
1.12that are waived under the federal Clinical Laboratory Improvement Act of 1988, United
1.13States Code, title 42, section 263a et seq., provided that a pharmacist may interpret the
1.14results of laboratory tests but may modify drug therapy only pursuant to a protocol or
1.15collaborative practice agreement;
1.16    (4) participation in drug and therapeutic device selection; drug administration for first
1.17dosage and medical emergencies; drug regimen reviews; and drug or drug-related research;
1.18    (5) participation in administration of influenza vaccines to all eligible individuals
1.19six years of age and older and all other vaccines to patients 13 years of age and older
1.20by written protocol with a physician licensed under chapter 147, a physician assistant
1.21authorized to prescribe drugs under chapter 147A, or an advanced practice registered
1.22nurse authorized to prescribe drugs under section 148.235, provided that:
1.23(i) the protocol includes, at a minimum:
1.24(A) the name, dose, and route of each vaccine that may be given;
1.25(B) the patient population for whom the vaccine may be given;
1.26(C) contraindications and precautions to the vaccine;
1.27(D) the procedure for handling an adverse reaction;
2.1(E) the name, signature, and address of the physician, physician assistant, or
2.2advanced practice registered nurse;
2.3(F) a telephone number at which the physician, physician assistant, or advanced
2.4practice registered nurse can be contacted; and
2.5(G) the date and time period for which the protocol is valid;
2.6    (ii) the pharmacist has successfully completed a program approved by the
2.7Accreditation Council for Pharmacy Education specifically for the administration of
2.8immunizations or a program approved by the board;
2.9    (iii) the pharmacist utilizes the Minnesota Immunization Information Connection
2.10to assess the immunization status of individuals prior to the administration of vaccines,
2.11except when administering influenza vaccines to individuals age nine and older;
2.12    (iv) the pharmacist reports the administration of the immunization to the Minnesota
2.13Immunization Information Connection; and
2.14(v) the pharmacist complies with guidelines for vaccines and immunizations
2.15established by the federal Advisory Committee on Immunization Practices, except that a
2.16pharmacist does not need to comply with those portions of the guidelines that establish
2.17immunization schedules when administering a vaccine pursuant to a valid, patient-specific
2.18order issued by a physician licensed under chapter 147, a physician assistant authorized to
2.19prescribe drugs under chapter 147A, or an advanced practice nurse authorized to prescribe
2.20drugs under section 148.235, provided that the order is consistent with the United States
2.21Food and Drug Administration approved labeling of the vaccine;
2.22    (6) participation in the initiation, management, modification, and discontinuation
2.23of drug therapy according to a written protocol or collaborative practice agreement
2.24between: (i) one or more pharmacists and one or more dentists, optometrists, physicians,
2.25podiatrists, or veterinarians; or (ii) one or more pharmacists and one or more physician
2.26assistants authorized to prescribe, dispense, and administer under chapter 147A, or
2.27advanced practice nurses authorized to prescribe, dispense, and administer under section
2.28148.235 . Any changes in drug therapy made pursuant to a protocol or collaborative
2.29practice agreement must be documented by the pharmacist in the patient's medical record
2.30or reported by the pharmacist to a practitioner responsible for the patient's care;
2.31    (7) participation in the storage of drugs and the maintenance of records;
2.32    (8) patient counseling on therapeutic values, content, hazards, and uses of drugs
2.33and devices; and
2.34    (9) offering or performing those acts, services, operations, or transactions necessary
2.35in the conduct, operation, management, and control of a pharmacy.; and
3.1    (10) participation in the initiation, management, modification, and discontinuation of
3.2therapy with opiate antagonists, as defined in section 604A.04, subdivision 1, pursuant to:
3.3    (i) a written protocol as allowed under clause (6); or
3.4    (ii) a written protocol with a community health board medical consultant or a
3.5practitioner designated by the commissioner of health, as allowed under section 151.37,
3.6subdivision 13.
"3.7Page 5, after line 28, insert:

"3.8    Sec. 7. Minnesota Statutes 2014, section 151.37, is amended by adding a subdivision
3.9to read:
3.10    Subd. 13. Opiate antagonists protocol. (a) The board shall develop an opiate
3.11antagonist protocol. When developing the protocol, the board shall consult with the Board
3.12of Medical Practice, the Board of Nursing, the commissioner of health, and professional
3.13associations of pharmacists, physicians, physician assistants, and advanced practice
3.14registered nurses.
3.15(b) The commissioner of health shall provide the following items to medical
3.16consultants appointed under section 145A.04, subdivision 2a:
3.17(1) educational materials concerning the need for, and opportunities to provide,
3.18greater access to opiate antagonists;
3.19(2) the opiate antagonist protocol developed by the board under paragraph (a); and
3.20(3) a notice of the liability protections under section 604A.04, subdivision 3, that are
3.21extended to cover the use of the opiate antagonist protocol developed under this subdivision.
3.22(c) The commissioner of health may designate a practitioner who is authorized to
3.23prescribe opiate antagonists to enter into the written protocol developed under paragraph
3.24(a) with pharmacists practicing within one or more community health service areas,
3.25upon the request of the applicable community health board. A community health board
3.26making a request to the commissioner under this section must do so by October 1 for the
3.27subsequent calendar year.
3.28(d) The immunity in section 604A.04, subdivision 3, is extended to both the
3.29commissioner of health and to the designated practitioner when prescribing according
3.30to the protocol under this subdivision. The commissioner of health and the designated
3.31practitioner are both deemed to be acting within the scope of employment for purposes
3.32of section 3.736, subdivision 9, when prescribing according to the protocol under this
3.33subdivision.
"3.34Renumber the sections in sequence and correct the internal references
3.35Amend the title accordingly